Kodiak Sciences Inc. (KOD)
| Market Cap | 4.40B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -159.15M |
| Shares Out | 51.27M |
| EPS (ttm) | -3.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $85.78 |
| Previous Close | $84.77 |
| Change ($) | 1.01 |
| Change (%) | 1.19% |
| Day's Open | 85.03 |
| Day's Range | 81.83 - 85.89 |
| Day's Volume | 184,481 |
| 52-Week Range | 44.25 - 171.21 |
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock?
PALO ALTO, Calif., May 20, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kodiak Sciences Inc. ("Kodiak" or the "Company") (NASDAQ: KOD). Such investors are advised to cont...
Kodiak Sciences (KOD) reports wider-than-expected loss for the first quarter of 2021. Pipeline development remains in focus for the company.
The company provided a first-quarter update with news that it's launching another late-stage clinical study of its lead candidate.
PALO ALTO, Calif., May 10, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PALO ALTO, Calif., April 21, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to ...
Kodiak Sciences (KOD) reports wider-than-expected loss in the fourth quarter of 2020. The company is making good progress with the development of its lead pipeline candidate, KSI-301.
PALO ALTO, Calif., March 1, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
Kodiak Sciences Inc (NASDAQ: KOD) announced new data from one-year durability, efficacy, and safety data from the ongoing Phase 1b study evaluating KSI-301, an intravitreal anti-VEGF antibody biopolymer...
PALO ALTO, Calif., Feb. 13, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
PALO ALTO, Calif., Feb. 2, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
PALO ALTO, Calif., Jan. 5, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
PALO ALTO, Calif., Nov. 17, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
PALO ALTO, Calif., Nov. 12, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
PALO ALTO, Calif., Nov. 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to t...
Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.
PALO ALTO, Calif., Nov. 9, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
Biotech companies with IPOs of at least $50 million in the past three years have averaged an increase in share price of more than 42%. Gainers outpaced decliners by a ratio of two to one, according to a...
VANCOUVER, British Columbia & PALO ALTO, Calif.--(BUSINESS WIRE)---- $KOD #AbCellera--AbCellera and Kodiak Sciences Inc. (Nasdaq: KOD), today announced a new partnership to generate therapeutic antibody...
Despite recent run-ups, these two have what takes to keep rising.
PALO ALTO, Calif., Oct. 5, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.
PALO ALTO, Calif., Aug. 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc.
PALO ALTO, Calif., July 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc.
PALO ALTO, Calif., July 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retin...
Kodiak Sciences (KOD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
As of late, it has definitely been a great time to be an investor in Kodiak Sciences
Kodiak Sciences Inc. (KOD) CEO Victor Perlroth on Q1 2020 Results - Earnings Call Transcript
These are the small cap stocks with the best value, fastest growth, and most momentum for May.
These three developmental-stage pharma stocks are attracting some of the smartest investors right now.
Coronavirus Has Presented A Buying Opportunity In Kodiak Sciences
These are the biotechnology stocks with the best value, fastest growth, and most momentum for Q2 2020.
Kodiak Sciences Inc’s (NASDAQ: KOD) main drug candidate, KSI-301, highlights the company’s focus on innovation in a dynamic treatment landscape, according to Goldman Sachs.
After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfo...
Kodiak Sciences: Stock That Skyrocketed In December
These stocks have soared 935% or more this year. Can they keep the momentum going?
Here's why these drugmaker stocks are the year's top performers.
Is (KOD) Outperforming Other Medical Stocks This Year?
Does Kodiak Sciences Inc. (KOD) have what it takes to be a top stock pick for momentum investors?
Kodiak Sciences Fully Funded And Ready To Potentially Change Wet-AMD Treatment
About KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage pr... [Read more...]
| Industry Biotechnology | IPO Date Oct 4, 2018 |
| Stock Exchange NASDAQ | Ticker Symbol KOD |
Analyst Forecasts
According to 11 analysts, the average rating for KOD stock is "Buy." The 12-month stock price forecast is 121.60, which is an increase of 41.76% from the latest price.